BC Extra | Oct 9, 2019
Company News

With Japan submission nearing in NMOSD, Viela picks Mitsubishi as territorial partner

Just days after completing its IPO, Viela will receive another cash infusion from a partnership giving Mitsubishi Tanabe territorial rights to lead program inebilizumab to treat neuromyelitis optical spectrum disorder. Viela Bio Inc. (NASDAQ:VIE) will...
BC Innovations | Oct 7, 2019
Distillery Therapeutics

Bispecific cytokine fusion for Type II diabetes

DISEASE CATEGORY: Endocrine/metabolic disease INDICATION: Diabetes A chimeric protein derived from two cytokines previously shown to modify food intake, IL-6 and CNTF, could treat Type II diabetes. The chimeric cytokine is based on IL-6, with...
BC Extra | Sep 26, 2019
Preclinical News

Sept. 26 Preclinical Quick Takes: $30M for new lung disease lab; plus AI-derived compounds from Auransa, Atomwise, and diabetes candidates

Bayer, Brigham and Mass General open lung disease-focused lab  Bayer AG (Xetra:BAYN) will invest more than $30 million over five years to fund research into new treatments for chronic lung diseases, such as chronic obstructive...
BC Extra | May 7, 2019
Clinical News

Viela reports detailed Phase II/III data for rare CNS disorder therapy

Viela touted a potential dosing advantage and reiterated its plans to submit mid-year a BLA to FDA for inebilizumab to treat neuromyelitis optica spectrum disorder (NMOSD). The update came during a presentation at AAN on...
BC Extra | Mar 26, 2019
Company News

Japan approvals include Kymriah as Japan's first CAR T therapy

Japanese regulators approved a basket of drugs on Tuesday, including the first CAR T cell therapy in Japan. Novartis AG (NYSE:NVS; SIX:NOVN) said Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Kymriah tisagenlecleucel to...
BioCentury | Jan 26, 2019
Product Development

Target wide, test narrow in lupus

While last year’s spate of clinical misses in lupus leave the field still in search of optimal targets, the 2019 outlook isn’t all doom. Companies with shots on goal are using sharper endpoints and aiming...
BC Week In Review | Jan 4, 2019
Clinical News

Viela planning BLA submission for inebilizumab in rare CNS disorder

Viela Bio Inc. (Gaithersburg, Md.) said it will submit a BLA to FDA this half for inebilizumab (MEDI-551) to treat neuromyelitis optica spectrum disorder (NMOSD) after the compound met the primary endpoint in the Phase...
BC Extra | Jan 3, 2019
Clinical News

Viela planning BLA submission for inebilizumab in rare CNS disorder

Viela Bio Inc. (Gaithersburg, Md.) said it will submit a BLA to FDA this half for inebilizumab (MEDI-551) to treat neuromyelitis optica spectrum disorder (NMOSD) after the compound met the primary endpoint in the Phase...
BC Week In Review | Dec 21, 2018
Clinical News

Chugai's IL-6 receptor mAb meets in Phase III for rare CNS disorder

Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) said satralizumab (SA237, RG6168) as monotherapy met the primary endpoint in the Phase III SAkuraStar trial to treat neuromyelitis optica spectrum disorder (NMOSD). The company plans to submit regulatory applications...
BC Extra | Dec 19, 2018
Clinical News

Chugai's IL-6 receptor mAb meets in Phase III for rare CNS disorder

Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) said satralizumab (SA237, RG6168) as monotherapy met the primary endpoint in the Phase III SAkuraStar trial to treat neuromyelitis optica spectrum disorder (NMOSD). The company plans to submit regulatory applications...
Items per page:
1 - 10 of 213